Quest Diagnostics and Mass General Brigham Launch Clinical Trials to Evaluate Haystack MRD ctDNA for Post-Surgical Cancer Treatment

Reuters
08/07
Quest Diagnostics and Mass General Brigham Launch Clinical Trials to Evaluate Haystack MRD ctDNA for Post-Surgical <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>

Quest Diagnostics Incorporated has announced a new research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital. This collaboration will focus on two clinical trials investigating the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test. The trials aim to evaluate its effectiveness as a tool for postoperative therapy decisions in cases of cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma. Led by Dr. Dan Faden and co-led by Sophia Shalhout, PhD, and Kevin Emerick, MD, the trials will assess Haystack MRD's impact on risk stratification and early detection of residual disease. Results of these studies have not yet been presented and will be available in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: NY43861) on August 07, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10